Article History
Received: 15 January 2024
Revised: 30 January 2024
Accepted: 31 January 2024
First Online: 26 February 2024
Competing interests
: LC has received consulting fees from Italfarmaco, Berlin Chemie, and Helsinn. AA has received honoraria from Pfizer, BMS, LeoPharma, and Recordati. MA has received consulting fee from Accord Pharmaceuticals, Amgen, BMS, Celgene, Clinigen Group, Daiichi Sankyo, Eisai, Eli Lilly, Genomic Health, G1 Therapeutics, GlaxoSmithKline, Helsinn, Hospira, Johnson & Johnson, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Teva Pharmaceuticals, and Vifor Pharma; has received honoraria from Astellas, Bayer HealthCare Pharmaceuticals, Biocon, Boeringer Ingelheim, Cephalon, Chugai Pharmaceutical, Dr Reddy’s Laboratories, Glenmark Pharmaceuticals, Ipsen, Janssen Biotech, Kyowa Kirin Group, Sanofi, and Taiho Pharmaceutical; has received grants from Amgen, Eisai, Genomic Health, Helsinn, Hospira, Novartis, Merck, Mundipharma, Pfizer, Roche, Sandoz, Tesaro, Teva Pharmaceuticals, Vifor Pharma.
: Not applicable.